-

09:50:21 PM

NYXH Stock News

NYXH -

06/30/22 4:30 PM

Nasdaq : NYXH

low float

Information on the total number of voting rights and shares

REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), June 30, 2022, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH)

RHEA-AI

neutral

06/07/22 4:30 PM

Nasdaq : NYXH

low float

Nyxoah Joins the Euronext Tech Leaders Initiative, Included in the Euronext Tech Leaders Index

Nyxoah Joins the Euronext Tech Leaders Initiative, Included in the Euronext Tech Leaders Index Mont-Saint-Guibert, Belgium – June 7, 2022 4:30pm ET / 10:30pm CET– Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and

RHEA-AI

very positive

06/01/22 4:30 PM

Nasdaq : NYXH

fda approvallow float

FDA Approves Genio® 2.1 For Use in DREAM U.S. IDE Pivotal Study

FDA Approves Genio® 2.1 For Use in DREAM U.S. IDE Pivotal Study New smartphone application, upgraded activation chip, improved user interface, and stimulation amplitude trimming enhance patient experience and comfort Mont-Saint-Guibert, Belgium – June 1, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA

RHEA-AI

very positive

05/10/22 2:55 AM

Nasdaq : NYXH

low float

Nyxoah Reports First Quarter 2022 Financial and Operating Results

REGULATED INFORMATION Nyxoah Reports First Quarter 2022 Financial and Operating Results Mont-Saint-Guibert, Belgium – May 10, 2022, 08:50pm CET / 2:50pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and

RHEA-AI

neutral

05/09/22 4:30 PM

Nasdaq : NYXH

low float

Nyxoah Reports First Quarter 2022 Financial and Operating Results

REGULATED INFORMATION Nyxoah Reports First Quarter 2022 Financial and Operating Results Mont-Saint-Guibert, Belgium – May 9, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and

RHEA-AI

neutral

05/06/22 1:00 AM

Nasdaq : NYXH

conferenceslow float

Invitation to attend the annual and the extraordinary shareholders’ meetings of the Company to be held on June 8, 2022

REGULATED INFORMATION May 6, 2022, 7:00am CET / 1:00am ET NYXOAH SA (Euronext Brussels: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium (hereinafter the “ Company ”) Invitation to attend the annual and the extraordinary shareholders’ meetings of the Company to be held on June 8, 2022

RHEA-AI

positive

05/06/22 1:00 AM

Nasdaq : NYXH

managementlow float

Nyxoah Nominates Raymond Cohen and Virginia Kirby for Appointment to Its Board of Directors

Nyxoah Nominates Raymond Cohen and Virginia Kirby for Appointment to Its Board of Directors Mont-Saint-Guibert, Belgium – May 6, 2022, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and

RHEA-AI

neutral

04/28/22 4:30 PM

Nasdaq : NYXH

earningslow float

Nyxoah to Release First Quarter 2022 Financial Results on May 9 and Host Conference Call on May 10, 2022

Nyxoah to Release First Quarter 2022 Financial Results on May 9 and Host Conference Call on May 10, 2022 Mont-Saint-Guibert, Belgium – April 28, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the

RHEA-AI

neutral

03/24/22 4:30 PM

Nasdaq : NYXH

earningslow float

Nyxoah Reports Full Year 2021 Operating and Financial Results

REGULATED INFORMATION Nyxoah Reports Full Year 2021 Operating and Financial Results Mont-Saint-Guibert, Belgium – March 24, 2022, 9:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and

RHEA-AI

neutral

03/14/22 6:30 PM

Nasdaq : NYXH

low float

BETTER SLEEP Achieves Primary Endpoint Across All Patient Cohorts

BETTER SLEEP Achieves Primary Endpoint Across All Patient Cohorts First clinical data demonstrating effectiveness of HGNS to treat CCC patients As previously disclosed, confirms achievement of primary endpoint of AHI4 reductions for entire population, CCC cohort, and non-CCC cohort at six months,

RHEA-AI

very positive